Treats motion sickness. ANDA 205723, held by Micro Labs. Diphenhydramine Hydrochloride.
As of Nov 22, 2026, ANDA 205723 (Diphenhydramine Hydrochloride), held by Micro Labs, was first approved by FDA on Aug 22, 2018, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness For active treatment of motion sickness.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 22, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diphenhydramine Hydrochloride50MG/ML · injectable;injection | Diphenhydramine Hydrochloride | Rx |
| Aug 29, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 30, 2018 | Supplement 1Manufacturing | Approved | None posted |
| Aug 22, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters